Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Empirican PRN Inc

Neither a doctor nor a teaching hospital

Research payments

$2,624,658

323 payments

Through program year 2025, Empirican PRN Inc is reported as receiving $2,624,658 in research payments, across 323 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $470,066 72
2024 Research $552,315 49
2023 Research $752,334 43
2022 Research $372,344 18
2021 Research $66,189 43
2020 Research $257,934 64
2019 Research $153,476 34

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $1,502,802 63 payments
  2. AbbVie, Inc. $388,349 97 payments
  3. Regeneron Pharmaceuticals, Inc. $246,556 58 payments
  4. GlaxoSmithKline, LLC. $183,433 54 payments
  5. Eli Lilly and Company $122,663 3 payments
  6. BioNTech SE $61,362 13 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $52,361 18 payments
  8. Sanofi US Services Inc. $19,500 1 payment
  9. Evofem Biosciences, Inc. $17,882 8 payments
  10. Celgene Corporation $13,500 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $1,374,600 52 payments
  2. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $233,543 54 payments
  3. M16-837 $139,553 16 payments
  4. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $128,202 11 payments
  5. A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Eval $126,670 35 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ Ly3650150 in Adult Participants With Perennial Allergic Rhinitis $107,723 2 payments
  7. Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis Bladder Pain Syndrome (IC BPS) $89,859 11 payments
  8. Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) $69,246 7 payments
  9. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $48,352 18 payments
  10. Fruquintinib $42,835 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $16,419 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record